Figure 4.

NVL-655 inhibits subcutaneous ALK-driven tumor xenografts in mice. A–D, Change in tumor volume over time plotted as mean ± SEM for models harboring ALK fusion with a WT kinase domain (A), G1202R single mutation (B), I1171N single mutation (C), or G1202R compound mutations (D). Horizontal gray lines denote mean starting tumor volume of the vehicle group. All treatments were administered orally twice daily, except alectinib 50 mg/kg and lorlatinib 10 mg/kg, which were administered orally once daily. Each group contained 4–9 mice.